USMLE Step 1 endocrine system questions

Hyperprolactinemia inhibits hypothalamic GnRH pulsatility, reducing LH and FSH secretion from the pituitary gonadotropes. This leads to hypogonadotropic hypogonadism, manifesting as amenorrhea and galactorrhea in women. The effect is reversible with treatment that lowers prolactin, such as dopamine agonists, which restore normal GnRH pulsatility. This is the central mechanism underlying reproductive dysfunction in prolactinomas of either sex.

• A. Prolactin does not increase SHBG synthesis as its main reproductive effect.
• B. Prolactin does not directly stimulate ovarian androgen overproduction.
• C. Stalk compression causing reduced dopamine delivery would raise, not explain, downstream prolactin effects, and anatomically the anterior stalk/portal vessels are affected, not isolated posterior pituitary compression causing amenorrhea.
• E. Prolactin does not act directly on ovarian aromatase to cause amenorrhea.

Cabergoline is an ergot-derived dopamine agonist that binds D2 receptors on pituitary lactotroph cells. Dopamine normally provides tonic inhibition of prolactin secretion and lactotroph proliferation via this receptor; D2 agonism mimics and enhances this inhibitory signal, lowering prolactin levels and causing lactotroph cell shrinkage and apoptosis, which reduces tumor size. This dual effect on hormone secretion and tumor bulk makes dopamine agonists first-line therapy for prolactinomas, in contrast to most other pituitary adenomas where medical therapy does not typically shrink tumor size.

• A. GnRH receptor agonists/antagonists act on gonadotropes, unrelated to prolactin control.
• B. GHRH receptor activation would stimulate somatotrophs, not lactotrophs.
• D. Somatostatin receptor agonists (e.g., octreotide) are used for GH- or TSH-secreting tumors, not prolactinomas.
• E. Estrogen receptor activation would stimulate rather than suppress lactotroph growth.

Because GH secretion is pulsatile, random GH levels are unreliable for diagnosing acromegaly. Serum IGF-1, which reflects integrated GH secretion over time, is the best initial screening test, and an elevated IGF-1 should be confirmed with an oral glucose suppression test (75 g glucose) measuring GH at baseline and subsequent time points. In normal physiology, glucose loading suppresses GH to less than 1 ng/mL; failure of suppression confirms autonomous GH hypersecretion, establishing the diagnosis of acromegaly.

• A. GHRH levels are not part of standard acromegaly diagnostic workup and are only relevant in rare ectopic GHRH-secreting tumors.
• C. Urine free cortisol is used to evaluate Cushing syndrome, not acromegaly.
• D. Insulin tolerance testing with GH measurement is used to evaluate for GH deficiency, not excess.
• E. Isolated prolactin, though sometimes co-secreted, does not confirm GH excess.

Growth hormone antagonizes insulin signaling in peripheral tissues, in part by impairing insulin receptor substrate (IRS) signaling, which reduces GLUT4 translocation to the cell membrane in skeletal muscle and adipose tissue. This decreases peripheral glucose uptake and promotes lipolysis, raising circulating free fatty acids that further worsen insulin resistance. The net effect is hyperglycemia and compensatory hyperinsulinemia, which can progress to overt diabetes mellitus in chronic GH excess, as seen in acromegaly.

• A. GH impairs rather than enhances hepatic insulin sensitivity.
• B. GH does not act primarily through glucagon suppression to cause hyperglycemia.
• D. GH does not cause autoimmune destruction of beta cells; this describes type 1 diabetes mechanisms, unrelated to acromegaly.
• E. GH does not act via SGLT2 upregulation in the kidney.

Sheehan syndrome results from ischemic necrosis of the anterior pituitary following severe postpartum hemorrhage with hypotension. During pregnancy, the anterior pituitary enlarges due to lactotroph hyperplasia but does not receive a proportional increase in blood supply, making it vulnerable to infarction during hypotensive episodes. This causes panhypopituitarism, classically presenting with failure of lactation (loss of prolactin), amenorrhea (loss of LH/FSH), and secondary hypothyroidism and adrenal insufficiency with low pituitary trophic hormones. The posterior pituitary is typically spared because it has a direct arterial supply.

• A. Cavernous sinus thrombosis is not the mechanism of postpartum pituitary ischemia in Sheehan syndrome.
• C. There is no indication of a pre-existing adenoma in this vignette; the mechanism is ischemia related to hemorrhage and hypotension.
• D. Sheehan syndrome is an ischemic, not autoimmune, process, and primarily affects the anterior, not posterior, pituitary.
• E. Lymphocytic hypophysitis is an autoimmune condition distinct from the ischemic mechanism of Sheehan syndrome, though it can also occur postpartum.

In central diabetes insipidus, the posterior pituitary fails to secrete adequate antidiuretic hormone (ADH), so urine remains inappropriately dilute despite water deprivation and a rising serum sodium, reflecting the body's inability to concentrate urine endogenously. Administration of exogenous desmopressin (a synthetic ADH analog) significantly increases urine osmolality because the renal collecting duct V2 receptors are intact and responsive, confirming that the defect is a lack of ADH rather than renal resistance to it. In contrast, nephrogenic DI would show minimal response to desmopressin because the kidney cannot respond to ADH regardless of its source.

• A. Osmotic diuresis from diabetes mellitus would show glucosuria and would not respond to desmopressin in this manner.
• C. Primary polydipsia typically shows low baseline serum sodium and urine osmolality that rises appropriately with water deprivation alone, without needing desmopressin.
• D. SIADH would present with hyponatremia and inappropriately concentrated urine, not dilute polyuria with hypernatremia.
• E. Nephrogenic DI would show a poor or absent urine osmolality response to desmopressin because renal V2 receptors are unresponsive.

Small cell lung cancer can ectopically secrete ADH, causing SIADH. This leads to water retention and dilutional hyponatremia, with serum osmolality inappropriately low while urine osmolality remains inappropriately high (greater than 100 mOsm/kg, and typically higher than serum osmolality) because ADH continues to promote water reabsorption in the collecting duct despite hypotonicity. Because the patient is euvolemic, the renin-angiotensin-aldosterone system is not activated to conserve sodium, so urine sodium remains elevated (often above 40 mEq/L), distinguishing SIADH from hypovolemic causes of hyponatremia.

• A. This patient's adrenal function is stated as normal, ruling out adrenal insufficiency as the cause.
• B. Primary polydipsia would produce dilute urine (low urine osmolality), not concentrated urine as seen here.
• C. True volume depletion would show appropriately low urine sodium (typically under 20 mEq/L) due to renal sodium conservation, not the elevated urine sodium seen here.
• D. This patient's lab pattern does not reflect aldosterone resistance, and renal function is normal.

Craniopharyngiomas arise from remnants of Rathke's pouch, classically showing an adamantinomatous histology with squamous epithelium, peripheral palisading, and calcifications resembling tooth enamel (keratin pearls), most common in children. Given their suprasellar location, these tumors characteristically compress the optic chiasm from below. At the chiasm, the nasal retinal fibers (which carry visual information from the temporal visual fields of each eye) cross to the contralateral side, so chiasmal compression selectively damages these crossing fibers, producing bitemporal hemianopia, loss of peripheral vision on both sides.

• A. Lateral geniculate nucleus lesions also produce contralateral homonymous visual field defects, not bitemporal hemianopia.
• B. Optic tract lesions occur after the chiasm and cause contralateral homonymous hemianopia, not bitemporal loss.
• D. Occipital cortex lesions typically cause homonymous visual field defects with possible macular sparing, not the bitemporal pattern described.
• E. Optic nerve compression causes unilateral monocular visual loss, not a bitemporal field cut.

This patient has medullary thyroid carcinoma (MTC) arising from calcitonin-secreting parafollicular C cells, confirmed by amyloid-positive stroma (calcitonin deposits) and a germline RET mutation, diagnostic of MEN2. Patients with MEN2A and MEN2B are at high risk for pheochromocytoma due to RET-driven adrenal medullary hyperplasia and tumor formation. Episodic hypertension, headache, and palpitations with elevated plasma free metanephrines are classic for catecholamine-secreting pheochromocytoma. All patients with MTC should be screened for RET mutations and, if positive, monitored for pheochromocytoma before any surgery to avoid an unrecognized catecholamine crisis.

• A. Zollinger-Ellison syndrome causes gastrin-driven peptic ulcers and diarrhea, not catecholamine excess, and is associated with MEN1, not MEN2.
• B. Insulinoma causes fasting hypoglycemia, not hypertensive episodes with elevated metanephrines, and is associated with MEN1.
• C. MEN2 can include primary hyperparathyroidism (parathyroid hyperplasia), but it does not cause episodic hypertension and elevated metanephrines.
• E. Carcinoid syndrome causes flushing and diarrhea from serotonin, not elevated metanephrines, and is not part of MEN2.

In levothyroxine overdose, exogenous T4 floods the circulation, producing a biochemical and clinical picture of thyrotoxicosis (tachycardia, tremor, diaphoresis) with markedly elevated free T4. The pituitary thyrotrophs sense the high circulating thyroid hormone via negative feedback and shut down TSH secretion, so TSH is appropriately suppressed to undetectable levels. This pattern (high T4, low TSH) is physiologic negative feedback, not autoimmune or autonomous thyroid gland activity. Distinguishing exogenous overdose from endogenous hyperthyroidism relies on history and a low radioactive iodine uptake scan, since the thyroid gland itself is not overactive.

• A. Subacute thyroiditis releases preformed hormone from gland destruction, typically with neck pain and low iodine uptake, not an acute pill overdose.
• B. A toxic adenoma autonomously produces hormone and would show focal increased iodine uptake, inconsistent with an acute ingestion.
• C. A TSH-secreting pituitary adenoma would cause elevated, not suppressed, TSH alongside elevated free T4.
• E. This describes Graves disease (TSI stimulating the TSH receptor), which would show increased radioactive iodine uptake, not an exogenous hormone overdose.

This infant's macroglossia, umbilical hernia, hypotonia, hoarse cry, lethargy, and constipation are classic features of congenital hypothyroidism (cretinism). Worldwide, the most common cause is maternal and infant iodine deficiency, since iodine is essential for thyroid hormone synthesis, and the fetus depends on adequate iodine (and transplacental maternal T4 in early gestation) for normal neurologic development. Untreated congenital hypothyroidism causes irreversible intellectual disability, making universal newborn TSH/T4 screening critical for early detection and treatment. In iodine-sufficient countries, thyroid dysgenesis is the more common cause, but iodine deficiency remains the leading global cause.

• B. Autoimmune neonatal hypothyroidism from transplacental maternal antibodies is a rare cause and not linked to this patient's epidemiologic risk factor.
• C. Pituitary aplasia causing central hypothyroidism is rare and would not be specifically linked to lack of iodized salt.
• D. An activating TSH receptor mutation causes congenital hyperthyroidism, not hypothyroidism.
• E. 21-hydroxylase deficiency causes congenital adrenal hyperplasia with virilization and salt-wasting, not the findings described here.

This pattern, low T3, low-normal free T4, low or low-normal TSH, and elevated reverse T3, in a critically ill patient without prior thyroid disease, is characteristic of sick euthyroid syndrome (nonthyroidal illness syndrome). Systemic illness and cytokine release (such as TNF-alpha and IL-6) inhibit peripheral deiodinase activity, reducing conversion of T4 to active T3 and favoring production of inactive reverse T3 instead. TSH is also suppressed because cytokines blunt hypothalamic TRH release. These changes are an adaptive response to severe illness, not primary thyroid or pituitary disease, and thyroid hormone replacement is not indicated.

• A. Pituitary infarction would be expected to cause low TSH with low T4, but would not characteristically show the elevated reverse T3 seen here, and there is no history to support it.
• B. Iodine-induced thyrotoxicosis would present with low TSH and elevated, not low, T4 and T3.
• C. Thyroid hormone resistance presents with elevated T3/T4 and inappropriately normal or elevated TSH, not this low T3/low T4 pattern.
• D. Autoimmune thyroiditis (Hashimoto) would show elevated TSH with low T4 and typically antithyroid antibodies, not this pattern.

The combination of elevated calcium, low phosphate, and inappropriately elevated (rather than suppressed) intact PTH, with a single enlarged parathyroid gland on imaging, is diagnostic of primary hyperparathyroidism, most commonly from a solitary parathyroid adenoma. The adenoma autonomously secretes PTH independent of the normal calcium feedback loop, which increases bone resorption, renal calcium reabsorption, phosphate wasting, and 1-alpha-hydroxylase activity, raising serum calcium and urine calcium while lowering phosphate. This biochemical profile distinguishes primary hyperparathyroidism from other hypercalcemic states, which typically suppress PTH.

• A. PTHrP-mediated hypercalcemia of malignancy suppresses endogenous PTH rather than elevating intact PTH, and would not show an enlarged parathyroid gland.
• C. Chronic kidney disease causes phosphate retention (high phosphate) with secondary hyperparathyroidism, typically with low or normal calcium, not elevated calcium with low phosphate.
• D. Vitamin D intoxication causes hypercalcemia with elevated phosphate and suppressed PTH, not elevated PTH with low phosphate.
• E. Granulomatous disease increases calcitriol production, causing hypercalcemia with suppressed PTH, not elevated PTH with a discrete adenoma.

Squamous cell carcinoma of the lung commonly causes humoral hypercalcemia of malignancy by secreting PTH-related peptide (PTHrP), which shares N-terminal sequence homology with PTH and binds the same PTH/PTHrP receptor (PTH1R) in bone and kidney. This activates the same downstream effects as PTH, osteoclastic bone resorption and renal calcium reabsorption with phosphate wasting, producing hypercalcemia and hypophosphatemia. However, intact PTH assays do not detect PTHrP, so measured PTH is appropriately suppressed due to feedback from the hypercalcemia. This distinguishes humoral hypercalcemia of malignancy from primary hyperparathyroidism, where intact PTH is elevated.

• B. Hyperthyroidism can mildly increase bone turnover, but this is not the mechanism of hypercalcemia in lung squamous cell carcinoma.
• C. Lymphomas, not squamous cell carcinomas, are more classically associated with ectopic calcitriol production causing hypercalcemia.
• D. Direct osteolytic metastasis (as in multiple myeloma or breast cancer bone metastases) causes local bone destruction but is not the typical mechanism for squamous cell lung cancer and does not explain the systemic phosphate wasting pattern described.
• E. The tumor secretes a PTH-like peptide, not actual PTH; ectopic PTH secretion by non-parathyroid tumors is extremely rare.

In chronic kidney disease, failing kidneys lose 1-alpha-hydroxylase activity, reducing conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol). Reduced calcitriol decreases intestinal calcium absorption, and declining GFR causes phosphate retention; both hypocalcemia and hyperphosphatemia directly stimulate parathyroid hormone secretion. The persistently low calcium and high phosphate drive chronic parathyroid gland stimulation and hyperplasia, producing secondary hyperparathyroidism with very high PTH levels and resorptive bone changes. Unlike primary hyperparathyroidism, this process is a secondary, physiologic response to chronic metabolic derangement rather than autonomous gland pathology.

• B. PTHrP from a tumor would suppress endogenous PTH and typically cause hypercalcemia, not this pattern of CKD-related hypocalcemia with elevated intact PTH.
• C. An autonomous adenoma describes primary, not secondary, hyperparathyroidism, and would not explain the low calcium and high phosphate from renal failure.
• D. Autoimmune parathyroid destruction causes hypoparathyroidism with low PTH, the opposite of this presentation.
• E. A calcium-sensing receptor loss-of-function mutation causes familial hypocalciuric hypercalcemia, not this CKD-driven process.

This infant has DiGeorge syndrome, caused by a 22q11.2 microdeletion that disrupts development of the third and fourth pharyngeal pouches. These pouches normally give rise to the parathyroid glands and thymus, so their failure to develop produces hypoparathyroidism (hypocalcemic seizures, low PTH) and thymic aplasia (absent thymic shadow, T-cell immunodeficiency), alongside conotruncal cardiac defects and cleft palate from associated neural crest and pharyngeal arch anomalies. The low PTH directly explains the hypocalcemia and hyperphosphatemia, since PTH normally increases calcium and decreases phosphate.

• B. A calcium-sensing receptor gain-of-function mutation causes autosomal dominant hypoparathyroidism, a distinct genetic cause unrelated to 22q11.2 deletion and pharyngeal pouch defects.
• C. 1-alpha-hydroxylase deficiency (vitamin D-dependent rickets type 1) causes hypocalcemia with elevated, not low, PTH.
• D. Pseudohypoparathyroidism involves target-organ resistance to PTH with elevated, not low, PTH levels.
• E. Autoimmune parathyroid destruction (as in autoimmune polyendocrine syndrome type 1) occurs later in childhood, not as a congenital 22q11.2 deletion presentation.

Pseudohypoparathyroidism type 1A results from an inactivating mutation in GNAS1, which encodes the stimulatory G protein alpha subunit (Gs-alpha) coupled to the PTH receptor. Renal tubular cells fail to respond to PTH despite normal or elevated hormone levels, producing hypocalcemia and hyperphosphatemia with compensatory secondary hyperparathyroidism (end-organ resistance). Because the mutation is present in all Gs-alpha-coupled tissues, patients also show the somatic features of Albright hereditary osteodystrophy, including short stature, obesity, round face, and shortened fourth/fifth metacarpals (brachydactyly). PTH administration fails to raise urinary cAMP or phosphate excretion, confirming the renal resistance.

• A. Parathyroid gland destruction causes primary hypoparathyroidism with low PTH, not elevated PTH.
• C. Vitamin D receptor resistance does not explain the failure of exogenous PTH to raise urinary cAMP.
• D. This describes autoimmune hypoparathyroidism, which would cause low rather than elevated PTH.
• E. A deleted PTH gene would cause absent PTH, not elevated PTH with end-organ resistance.

Chvostek sign (facial twitching with tapping over the facial nerve) and Trousseau sign (carpal spasm with blood pressure cuff inflation) are classic signs of neuromuscular irritability caused by hypocalcemia. The most common cause after total thyroidectomy is inadvertent removal, devascularization, or bruising of the parathyroid glands, which are small, closely adherent to the thyroid, and dependent on a delicate blood supply. This leads to acute hypoparathyroidism with low PTH, hypocalcemia, and hyperphosphatemia, manifesting within the first 24-48 hours postoperatively. Perioral numbness and acral paresthesias are early symptoms that precede overt tetany.

• B. Recurrent laryngeal nerve injury causes hoarseness or airway compromise, not hypocalcemic tetany.
• C. Transient hypothyroidism develops over weeks, not within one day, and does not cause acute tetany.
• D. Hungry bone syndrome occurs after parathyroidectomy for severe hyperparathyroidism, not routine thyroidectomy.
• E. A hematoma would cause signs of airway obstruction (stridor, swelling), not isolated neuromuscular irritability.

Elevated ACTH confirms an ACTH-dependent cause of Cushing syndrome, eliminating primary adrenal tumors (which suppress ACTH via negative feedback) and exogenous steroid use. Among ACTH-dependent causes, a pituitary corticotroph adenoma (Cushing disease) retains partial responsiveness to negative feedback, so high-dose dexamethasone (a potent synthetic glucocorticoid) suppresses cortisol production by more than 50%. In contrast, ectopic ACTH-secreting tumors are typically autonomous and resistant to suppression even at high dexamethasone doses, so cortisol fails to decrease significantly. This pattern of elevated ACTH with significant suppression on high-dose testing localizes the source to the pituitary.

• A. Adrenal adenomas are ACTH-independent and would be associated with a suppressed, not elevated, serum ACTH.
• B. Ectopic ACTH sources are typically resistant to high-dose dexamethasone suppression, unlike this patient's 75% suppression.
• D. Adrenal carcinoma is ACTH-independent and would present with suppressed ACTH, not an elevated level.
• E. Exogenous steroid use suppresses endogenous ACTH, which would be low, not elevated.

Cushing disease arises from a corticotroph adenoma, a benign pituitary tumor composed of ACTH-secreting cells that autonomously overproduce ACTH, driving excess cortisol synthesis by the adrenal cortex. These tumor cells retain glucocorticoid receptors but require a much higher cortisol concentration to suppress ACTH release, explaining failure to suppress with low-dose dexamethasone but partial suppression (>50%) with high-dose dexamethasone. This shifted feedback threshold, rather than complete loss of feedback sensitivity, distinguishes corticotroph adenomas from ectopic ACTH-secreting tumors, which are generally unresponsive even to high-dose suppression.

• B. Somatotroph adenomas cause acromegaly through growth hormone excess, not primary ACTH hypersecretion.
• C. Null cell adenomas are hormonally inactive and typically present with mass effect and hypopituitarism, not ACTH excess.
• D. Craniopharyngiomas disrupt dopamine inhibition of prolactin, causing hyperprolactinemia, not ACTH-driven Cushing syndrome.
• E. Lactotroph adenomas secrete prolactin and cause galactorrhea or amenorrhea, not primarily ACTH excess.

This patient's combination of resistant hypertension and unprovoked hypokalemia raises suspicion for primary hyperaldosteronism (Conn syndrome), most commonly caused by an aldosterone-producing adrenal adenoma or bilateral adrenal hyperplasia. The plasma aldosterone-to-renin ratio is the recommended initial screening test, because autonomous aldosterone secretion suppresses renin release via volume expansion and negative feedback, producing a markedly elevated ratio (typically greater than 20-30 with aldosterone concentration above 15 ng/dL). A positive screen is followed by a confirmatory suppression test such as oral sodium loading before imaging localization. Measuring renin alone without aldosterone would miss the characteristic combination of high aldosterone with suppressed renin.

• A. Renin alone without a paired aldosterone measurement cannot establish the characteristic high-aldosterone, low-renin state.
• B. The captopril challenge test is a confirmatory test used after an abnormal aldosterone-to-renin ratio, not the initial screening step.
• D. Plasma metanephrines screen for pheochromocytoma, which classically presents with episodic hypertension, palpitations, and headache rather than this pattern.
• E. Urinary cortisol evaluates for Cushing syndrome, which does not typically cause this degree of isolated hypokalemia with resistant hypertension.

Spironolactone is a potassium-sparing diuretic that competitively antagonizes the mineralocorticoid receptor in the renal collecting duct, blocking aldosterone-mediated sodium reabsorption and potassium secretion, making it first-line therapy for primary hyperaldosteronism. Spironolactone also has off-target antiandrogenic activity, blocking androgen receptors, and weak progestogenic activity, which together shift the estrogen-to-androgen balance in breast tissue toward relative estrogen dominance. This hormonal effect produces gynecomastia and breast tenderness, a well-recognized dose-dependent adverse effect. Eplerenone is a more selective mineralocorticoid receptor antagonist with substantially lower rates of this adverse effect because it lacks significant antiandrogenic activity.

• A. Spironolactone does not inhibit aromatase; this is not its mechanism of causing gynecomastia.
• B. Spironolactone does not act on pituitary prolactin secretion.
• C. 5-alpha-reductase inhibition is the mechanism of drugs like finasteride, not spironolactone.
• D. Spironolactone does not directly upregulate estrogen receptor expression in breast tissue.

Classic salt-wasting congenital adrenal hyperplasia is caused by 21-hydroxylase deficiency, which blocks conversion of progesterone and 17-hydroxyprogesterone into deoxycorticosterone and 11-deoxycortisol. The resulting buildup of 17-hydroxyprogesterone is shunted into the androgen pathway, causing virilization of the external genitalia in a genetic female, while impaired cortisol and aldosterone synthesis produces salt wasting, hyperkalemia, and hyponatremia. Markedly elevated 17-hydroxyprogesterone is the diagnostic biochemical hallmark and is used in newborn screening. Low aldosterone and cortisol with compensatory high ACTH and renin complete the picture.

• A. Aldosterone is low, contributing to the salt-wasting crisis, not elevated.
• B. Testosterone is elevated, not decreased, causing the virilization seen.
• C. Deoxycorticosterone and renin would not both be elevated together in this pattern; renin is high due to volume depletion, not suppressed.
• E. ACTH is elevated, not decreased, due to loss of cortisol negative feedback.

11-beta-hydroxylase deficiency blocks conversion of 11-deoxycortisol to cortisol and deoxycorticosterone to corticosterone, causing accumulation of both 11-deoxycortisol and deoxycorticosterone (DOC). DOC is a weak mineralocorticoid receptor agonist that, when present in excess, activates renal mineralocorticoid receptors, increasing sodium and water reabsorption and potassium excretion. This expands intravascular volume and suppresses renin-angiotensin-aldosterone activity, producing hypertension with hypokalemia and low renin despite low aldosterone. Excess adrenal androgens from the shunted precursor pool cause virilization.

• A. 11-Deoxycortisol itself is not a significant vasoconstrictor; its accumulation is a marker, not the cause of hypertension.
• B. Renin is suppressed, not increased, due to volume expansion from DOC's mineralocorticoid activity.
• C. Aldosterone synthesis is actually reduced because substrate is shunted toward androgens and DOC accumulates upstream.
• E. Androgen excess causes virilization, not an estrogen-mediated mechanism, and estrogen conversion does not explain hypertension here.

Autoimmune destruction of the adrenal cortex (Addison disease) causes loss of cortisol-mediated negative feedback on the hypothalamic-pituitary axis, leading to increased hypothalamic CRH and pituitary production of proopiomelanocortin (POMC). POMC is cleaved into both ACTH and melanocyte-stimulating hormone (MSH). The elevated MSH binds melanocortin-1 receptors on melanocytes, increasing melanin synthesis and producing hyperpigmentation, particularly in sun-exposed areas, skin creases, and mucous membranes. This finding is specific to primary adrenal insufficiency and is absent in secondary adrenal insufficiency, where ACTH/POMC is low.

• A. Cortisol is low in this condition, and cortisol does not act on melanocortin receptors to cause pigmentation.
• B. Adrenal androgens are also deficient in Addison disease and have no role in skin pigmentation.
• C. The 21-hydroxylase antibodies destroy adrenal cortical cells; they do not cross-react with or stimulate melanocytes.
• D. Volume depletion causes pallor and poor perfusion, not hyperpigmentation.

Abrupt withdrawal of long-term exogenous glucocorticoids suppresses the hypothalamic-pituitary-adrenal axis, leaving the adrenal glands atrophic and unable to produce endogenous cortisol, which precipitates acute adrenal (addisonian) crisis. This is a medical emergency requiring immediate intravenous hydrocortisone, which has both glucocorticoid and mineralocorticoid activity, along with aggressive isotonic fluid resuscitation to correct hypotension and hyponatremia. Treatment must not be delayed for confirmatory hormone testing in a hemodynamically unstable patient. Oral therapy is inadequate given impaired absorption and the severity of shock.

• A. Oral dosing is inappropriate in a hypotensive, vomiting patient who needs rapid intravenous therapy.
• C. Fludrocortisone alone lacks sufficient glucocorticoid activity and does not address the cortisol deficiency or hypoglycemia.
• D. Furosemide would worsen hypotension and hyponatremia in a volume-depleted patient.
• E. Treatment should never be delayed for laboratory confirmation in a patient with hemodynamic instability suggestive of adrenal crisis.

Waterhouse-Friderichsen syndrome occurs in fulminant Neisseria meningitidis sepsis, where endotoxin-driven activation of the coagulation cascade produces disseminated intravascular coagulation (DIC). Microthrombi form in the small vessels of the adrenal glands, leading to venous congestion, hemorrhagic infarction, and rapid destruction of adrenal cortical tissue. The resulting acute adrenal insufficiency compounds the septic shock already present from meningococcemia, contributing to refractory hypotension and death. This syndrome classically follows a purpuric rash and rapidly progressive meningococcemia.

• B. The process is acute and hemorrhagic, not a chronic granulomatous disease such as tuberculosis.
• C. Meningococcemia does not form metastatic deposits like a tumor; the adrenal injury is hemorrhagic and ischemic.
• D. The adrenal damage is due to coagulopathy and hemorrhage, not direct bacterial colonization of adrenal tissue.
• E. This is an acute septic and coagulopathic process, not an autoimmune vasculitic process.

Catecholamines from a pheochromocytoma act on both vasoconstrictive alpha-1 receptors and vasodilatory beta-2 receptors in peripheral vasculature. If a beta-blocker is given before adequate alpha blockade, blockade of beta-2-mediated vasodilation leaves alpha-1-mediated vasoconstriction unopposed, which can precipitate a severe hypertensive crisis. Therefore, alpha blockade with an agent such as phenoxybenzamine must be established first to control blood pressure, followed by beta blockade to control reflex tachycardia that results from the vasodilation and decreased peripheral resistance caused by alpha blockade. This sequence is essential before any surgical manipulation of the tumor.

• A. The sequence addresses hemodynamic control during the perioperative period, not postoperative adrenal insufficiency, which is not expected since the contralateral adrenal gland is intact.
• C. The correct order is alpha blockade first; giving a beta-blocker first is dangerous, not a prerequisite step.
• D. Beta-blockers control heart rate and reflex tachycardia; they do not suppress catecholamine release from the tumor.
• E. Phenoxybenzamine blocks alpha-adrenergic receptors; it does not inhibit catecholamine biosynthesis.

This patient's combination of bilateral pheochromocytomas, medullary thyroid carcinoma (reflected by the markedly elevated calcitonin, a product of thyroid C cells), and a family history consistent with autosomal dominant inheritance is classic for multiple endocrine neoplasia type 2 (MEN2). MEN2A and MEN2B are caused by germline gain-of-function mutations in the RET proto-oncogene, which encodes a receptor tyrosine kinase; constitutive activation drives proliferation of neural crest-derived cells, including adrenal medullary chromaffin cells and thyroid C cells. MEN2A also includes primary hyperparathyroidism, while MEN2B includes mucosal neuromas and a marfanoid habitus. Prophylactic thyroidectomy is recommended for RET mutation carriers.

• A. NF1 mutations cause neurofibromatosis type 1, which can be associated with pheochromocytoma but not medullary thyroid carcinoma.
• B. SDHB mutations are associated with paragangliomas and pheochromocytomas but not medullary thyroid carcinoma.
• C. VHL mutations cause von Hippel-Lindau disease, associated with pheochromocytoma and renal cell carcinoma, but not medullary thyroid carcinoma.
• D. MEN1 mutations cause tumors of the pituitary, parathyroid, and pancreas, not medullary thyroid carcinoma or pheochromocytoma.

This tumor arises from primitive sympathetic neuroblasts and is the most common extracranial solid tumor of childhood, typically presenting before age 5 as an abdominal mass that can cross the midline. Histology shows small round blue cells forming Homer Wright rosettes, which are clusters of cells surrounding a central core of neuritic (neurofibrillary) processes. Catecholamine metabolites (homovanillic acid and vanillylmandelic acid) are elevated, but hypertension and paroxysmal symptoms are less prominent than in pheochromocytoma because secretion is often continuous and the catecholamines produced are less potent. The absence of episodic hypertensive symptoms and the rosette histology favor this diagnosis over a catecholamine-secreting tumor of chromaffin cells.

• A. Adrenocortical carcinoma arises from the adrenal cortex and shows pleomorphic cells with features of steroid-producing cells, not neuroblasts.
• B. Pheochromocytoma arises from chromaffin cells, lacks Homer Wright rosettes, and classically causes episodic hypertension, palpitations, and sweating, which are absent here.
• C. Wilms tumor shows triphasic histology with blastemal, stromal, and epithelial elements, not small round blue cells with rosettes.
• D. Ganglioneuroma is a benign, well-differentiated tumor composed of mature ganglion cells without small round blue cell morphology.

Type 1 diabetes mellitus results from autoimmune destruction of pancreatic beta cells, mediated primarily by cytotoxic CD8+ T lymphocytes and CD4+ helper T cells directed against beta cell antigens such as glutamic acid decarboxylase (GAD65) and islet cell antigens. Autoantibodies against GAD and islet cells are useful diagnostic markers and reflect the underlying autoimmune process, but the actual beta cell killing is T cell-mediated rather than antibody-mediated. This leads to an absolute insulin deficiency, reflected by low insulin and C-peptide levels. Genetic susceptibility is linked to HLA-DR3 and HLA-DR4 haplotypes.

• A. Autoantibodies against insulin receptors cause a rare form of severe insulin resistance (type B insulin resistance), not type 1 diabetes.
• C. Chronic pancreatitis with exocrine fibrosis can cause secondary diabetes but is not the mechanism here, where the process is autoimmune and endocrine-specific.
• D. Decreased GLUT4 translocation reflects peripheral insulin resistance, the mechanism of type 2 diabetes, not the beta cell loss of type 1 diabetes.
• E. Amyloid (amylin) deposition in islets is a feature of long-standing type 2 diabetes, not the primary mechanism in type 1 diabetes.

In diabetic ketoacidosis, absolute insulin deficiency combined with excess glucagon and catecholamines activates hormone-sensitive lipase in adipocytes, releasing free fatty acids. These fatty acids are transported to the liver, where low insulin and high glucagon promote carnitine-mediated mitochondrial beta-oxidation and conversion to acetyl-CoA, which is then converted to the ketone bodies beta-hydroxybutyrate and acetoacetate. These are strong organic acids that dissociate and consume bicarbonate, producing a high anion gap metabolic acidosis, calculated here as 138 minus (95 plus 10) equals 33 mEq/L. Kussmaul respirations (rapid, deep breathing) represent the compensatory respiratory response to the metabolic acidosis.

• A. Vomiting typically causes loss of gastric acid leading to metabolic alkalosis, not the acidosis and elevated anion gap seen in this patient.
• B. Lactic acidosis can coexist with DKA in severe hypoperfusion but is not the primary mechanism of the elevated anion gap in a well-perfused patient with hyperglycemia and ketonuria.
• C. Renal tubular bicarbonate loss produces a normal anion gap (hyperchloremic) acidosis, not the elevated anion gap seen here.
• E. Hypoventilation causing CO2 retention produces respiratory acidosis, whereas this patient is hyperventilating (Kussmaul breathing) to compensate for a metabolic acidosis.

Insulin administration in DKA stimulates Na+/K+-ATPase pumps on cell membranes, particularly in skeletal muscle and the liver, driving potassium into cells along with glucose. Even though many patients with DKA have a total body potassium deficit from osmotic diuresis and vomiting, the measured serum potassium is often falsely normal or even elevated at presentation because acidosis shifts potassium out of cells. Once insulin therapy begins, this rapid intracellular shift can precipitate severe hypokalemia, manifesting as weakness, palpitations, and characteristic ECG changes such as flattened T waves and U waves, which is why potassium must be monitored closely and repleted during insulin therapy. This is the dominant and most clinically important mechanism of the acute drop in serum potassium seen within hours of starting insulin.

• B. Osmotic diuresis contributes to the total body potassium deficit over the preceding days but does not explain the acute drop occurring within hours of starting insulin.
• C. Correction of acidosis does contribute modestly to intracellular potassium shift, but the dominant and immediate effect after starting an insulin infusion is the direct stimulation of Na+/K+-ATPase by insulin.
• D. Isotonic saline does not meaningfully dilute serum potassium to this degree, and this is not the primary mechanism underlying the acute drop after insulin initiation.
• E. Vomiting contributes to the pre-existing total body potassium deficit but does not explain the acute intracellular shift occurring after insulin is started.

Cerebral edema is a feared complication of DKA treatment in children, occurring most often within the first 4 to 12 hours after therapy begins. It is thought to result from rapid changes in serum osmolality, particularly when fluids and glucose correction occur too quickly relative to the rate of clearance of intracellular osmotically active particles (such as idiogenic osmoles) that accumulated in brain cells during the hyperosmolar state. This creates an osmotic gradient favoring water movement into brain cells, raising intracranial pressure. The classic presentation includes headache, altered mental status, and the Cushing triad of hypertension, bradycardia, and irregular respirations, which signal impending herniation and require immediate treatment with mannitol or hypertonic saline.

• A. This patient's glucose of 240 mg/dL is not critically low, and hypoglycemia would cause tachycardia and hypotension rather than the Cushing triad described.
• B. DKA is not characteristically associated with a coagulopathy causing spontaneous intracranial hemorrhage in this setting.
• D. Meningitis would more typically present with fever and meningismus rather than the acute Cushing triad developing during DKA treatment.
• E. There is no mention of opioid administration, and respiratory depression would not produce the described hypertension and bradycardia pattern.

Type 2 diabetes mellitus is characterized by peripheral insulin resistance, in which target tissues such as skeletal muscle and liver fail to respond normally to insulin despite normal or elevated circulating insulin levels. Obesity contributes to this resistance through excess free fatty acids and altered secretion of adipokines (such as decreased adiponectin and increased resistin and TNF-alpha), which impair postreceptor insulin signaling, including defective activation of the IRS-1/PI3K/Akt pathway, leading to decreased GLUT4 translocation to the cell membrane. This postreceptor defect, rather than a reduction in receptor number, is the central mechanism of insulin resistance, and initially beta cells compensate with increased insulin secretion (hyperinsulinemia) until they eventually fail.

• A. Antireceptor antibodies cause type B insulin resistance syndrome, a rare autoimmune condition, not the common insulin resistance of obesity-related type 2 diabetes.
• B. GLP-1 deficiency is not the primary driver of type 2 diabetes pathophysiology; the incretin effect is often blunted secondarily rather than causally deficient.
• C. Autoimmune beta cell destruction describes the mechanism of type 1 diabetes, not the insulin resistance seen in obese patients with type 2 diabetes.
• E. A structurally abnormal insulin molecule is an extremely rare cause of diabetes and would not explain elevated insulin levels with preserved receptor numbers.

Metformin's primary mechanism of action is activation of AMP-activated protein kinase (AMPK) in hepatocytes, which suppresses hepatic gluconeogenesis by downregulating key gluconeogenic enzymes and reducing mitochondrial production of ATP needed to drive this pathway. It also modestly increases peripheral insulin sensitivity and glucose uptake in skeletal muscle. Because metformin does not stimulate insulin release from pancreatic beta cells, it does not cause hypoglycemia when used as monotherapy, distinguishing it from insulin secretagogues such as sulfonylureas.

• A. Sitagliptin is a DPP-4 inhibitor that increases incretin levels, promoting glucose-dependent insulin secretion, which does not match this mechanism.
• C. Acarbose inhibits intestinal alpha-glucosidase to delay carbohydrate absorption and does not act on hepatic AMPK or gluconeogenesis.
• D. Pioglitazone is a thiazolidinedione that works by activating PPAR-gamma receptors to increase insulin sensitivity, not by activating AMPK in hepatocytes.
• E. Glyburide is a sulfonylurea that stimulates insulin secretion by closing ATP-sensitive potassium channels on beta cells, which is explicitly excluded in this stem.

Metformin is renally cleared, and in patients with significant renal impairment, it can accumulate to toxic levels. At high concentrations, metformin inhibits mitochondrial complex I of the electron transport chain, impairing oxidative phosphorylation and shifting cellular metabolism toward anaerobic glycolysis, which increases lactate production while also impairing hepatic lactate clearance via gluconeogenesis inhibition. This produces metformin-associated lactic acidosis, a rare but potentially fatal complication that presents with an elevated anion gap, markedly elevated lactate, hypotension, and altered mental status, especially in the setting of acute kidney injury that further reduces drug clearance. This is why metformin is contraindicated or used cautiously in patients with significant renal impairment.

• A. Metformin is not associated with hemolysis; the tissue hypoxia and lactate elevation result from impaired mitochondrial oxidative metabolism, not from reduced oxygen-carrying capacity.
• B. Metformin is not a direct nephrotoxin; the kidney injury here is unrelated to metformin and instead causes reduced drug clearance, worsening the metabolic complication.
• C. Metformin does not act on the central respiratory center; the tachypnea seen here is a compensatory response to metabolic acidosis, not primary respiratory depression.
• D. Metformin does not promote glycogenolysis; it suppresses hepatic glucose output through decreased gluconeogenesis, which is unrelated to the mechanism of lactic acidosis.

Sulfonylureas (e.g., glyburide, glimepiride) bind the SUR1 subunit of the ATP-sensitive potassium (K-ATP) channel on pancreatic beta cells, closing the channel. This prevents potassium efflux, causing membrane depolarization, which opens voltage-gated calcium channels. The resulting calcium influx triggers exocytosis of insulin-containing granules. This mechanism requires some residual beta-cell function, which is why sulfonylureas are ineffective in type 1 diabetes.

• A. This is the target of GLP-1 agonists such as exenatide, acting through a G protein-coupled receptor.
• B. This is the renal transporter inhibited by SGLT2 inhibitors like empagliflozin.
• C. This is the nuclear receptor target of thiazolidinediones, not sulfonylureas.
• E. Calcium channels open secondarily to depolarization but are not the direct binding site of sulfonylureas.

Sulfonylureas cause insulin release by closing K-ATP channels regardless of the ambient blood glucose concentration, unlike normal physiologic insulin secretion which is tightly glucose-dependent. This non-glucose-dependent stimulation can produce prolonged and recurrent hypoglycemia, especially with long-acting agents like glyburide or in elderly patients with renal insufficiency who have reduced drug clearance. Hypoglycemia is the most common and serious adverse effect of sulfonylureas, more frequent than with metformin or DPP-4 inhibitors.

• A. Sulfonylureas do not directly inhibit glycogen breakdown enzymes in the liver.
• B. This describes a mechanism relevant to SGLT2 inhibitors, not sulfonylureas, and would cause hyperglycemia if reversed.
• C. Glucagon secretion changes are not the primary driver of sulfonylurea-induced hypoglycemia.
• D. Sulfonylureas do not act by improving peripheral tissue sensitivity to insulin; that is the mechanism of thiazolidinediones.

Thiazolidinediones (e.g., pioglitazone, rosiglitazone) activate PPAR-gamma, a nuclear receptor that regulates adipocyte differentiation and insulin sensitivity, but also increases expression of epithelial sodium channels in the renal collecting duct. This promotes sodium and water retention, which can precipitate or worsen peripheral edema and congestive heart failure, particularly in patients with pre-existing renal or cardiac disease. For this reason, thiazolidinediones are contraindicated in patients with New York Heart Association class III-IV heart failure.

• A. SGLT2 inhibitors, not thiazolidinediones, cause osmotic diuresis; thiazolidinediones cause fluid retention, not diuresis.
• B. Thiazolidinediones cause fluid overload through sodium retention, not direct myocardial toxicity or cardiomyopathy.
• D. The edema results from volume overload due to sodium retention, not increased capillary leakage of fluid into tissues.
• E. Thiazolidinediones do not act by suppressing natriuretic peptide release; fluid retention is a renal tubular sodium effect.

Hyperosmolar hyperglycemic state (HHS), typical of type 2 diabetes, occurs when residual endogenous insulin secretion remains sufficient to suppress lipolysis and ketogenesis, even though it cannot adequately control hyperglycemia. This contrasts with diabetic ketoacidosis (DKA), seen predominantly in type 1 diabetes with near-total insulin deficiency, where unchecked lipolysis generates excess free fatty acids converted to ketone bodies, causing an anion gap metabolic acidosis. HHS is characterized by extreme hyperglycemia (often >600 mg/dL), markedly elevated serum osmolality, and profound dehydration with minimal ketosis or acidosis, and it classically presents with altered mental status in elderly patients with type 2 diabetes.

• A. There is no evidence of alkalosis in this patient, and this would not explain an absence of ketogenesis.
• B. Counterregulatory hormones (glucagon, cortisol, catecholamines) are elevated in both HHS and DKA; their absence is not the distinguishing feature.
• C. Enhanced hepatic ketone utilization is not a recognized mechanism preventing ketoacidosis in HHS.
• E. Renal ketone clearance is not the primary mechanism differentiating HHS from DKA.

Chronic hyperglycemia drives nonenzymatic glycation of proteins in the glomerular basement membrane and mesangial matrix, forming advanced glycation end products that cross-link collagen and increase basement membrane permeability and thickness. This process, along with glycation-induced mesangial matrix expansion, produces the nodular (Kimmelstiel-Wilson) glomerulosclerosis characteristic of diabetic nephropathy, along with diffuse glomerulosclerosis. Hyperglycemia also causes efferent arteriolar hyalinization, increasing glomerular filtration pressure and accelerating glomerular injury, which together with glycation explains the progression to proteinuria.

• A. Immune complex deposition is characteristic of lupus nephritis or post-streptococcal glomerulonephritis, not diabetic nephropathy.
• B. Complement-mediated endothelial lysis is not the mechanism underlying diabetic glomerular basement membrane thickening.
• C. Amyloidosis produces apple-green birefringence under polarized light with Congo red stain, not nodular PAS-positive glycation deposits.
• E. Primary podocyte antibody attack describes membranous nephropathy, not the glycation-driven injury of diabetic nephropathy.

In states of chronic hyperglycemia, excess intracellular glucose in tissues that do not require insulin for glucose uptake, such as peripheral nerves, lens, and kidney, is shunted through the polyol pathway. Aldose reductase, using NADPH, reduces glucose to sorbitol, which accumulates intracellularly because many of these tissues have low or absent sorbitol dehydrogenase activity to convert it further to fructose. The resulting intracellular sorbitol accumulation causes osmotic stress and depletes NADPH needed for glutathione regeneration, contributing to oxidative damage, Schwann cell dysfunction, and the peripheral neuropathy seen in diabetes.

• B. Sorbitol dehydrogenase converts sorbitol to fructose downstream; its relative deficiency in nerve tissue contributes to sorbitol accumulation, but it is not the enzyme that initiates glucose conversion to sorbitol.
• C. Hexokinase phosphorylates glucose to glucose-6-phosphate in glycolysis and is not involved in sorbitol production.
• D. This enzyme functions in the pentose phosphate pathway generating NADPH, not in glucose-to-sorbitol conversion.
• E. This brush border enzyme breaks down dietary carbohydrates in the intestine and is unrelated to intracellular sorbitol accumulation.

Empty sella syndrome results from herniation of the subarachnoid space and CSF through an incompetent diaphragma sellae, which progressively compresses and flattens the pituitary gland against the floor of the sella. Over time this mechanical compression can destroy enough functioning pituitary tissue to cause panhypopituitarism, with sequential loss of gonadotropins, growth hormone, TSH, and ACTH. MRI classically shows an enlarged, CSF-filled sella with a thin rim of pituitary tissue and no discrete mass, distinguishing it from a tumor. Primary empty sella is most common in obese, multiparous women and is a recognized cause of hypopituitarism without an identifiable mass lesion.

• A. Craniopharyngioma is a suprasellar mass that would appear as a discrete lesion on MRI, not an empty, CSF-filled sella.
• B. Sheehan syndrome occurs after postpartum hemorrhage with pituitary infarction, not CSF herniation; there is no history of obstetric hemorrhage here.
• C. Pituitary apoplexy presents acutely with severe headache and often visual field defects, not a gradual indolent course with an empty sella on imaging.
• D. Autoimmune hypophysitis would typically show an enlarged, enhancing gland or stalk, not a CSF-filled empty sella.

Graves disease is caused by thyroid-stimulating immunoglobulins (TSIs) that bind the TSH receptor on follicular cells and act as agonists, mimicking TSH. This chronic receptor activation stimulates adenylate cyclase and cAMP production, driving excess synthesis and release of thyroid hormone as well as diffuse follicular hyperplasia and glandular enlargement with increased vascularity, producing the characteristic bruit. The autoantibodies are detected clinically as thyroid-stimulating immunoglobulin or TSH receptor antibody. This mechanism distinguishes Graves disease from thyroiditis, where gland destruction rather than stimulation predominates.

• A. T cell-mediated follicular destruction is the mechanism of Hashimoto thyroiditis, which causes hypothyroidism, not Graves disease.
• B. Blocking antibodies occur in some autoimmune thyroid conditions and cause hypothyroidism, not the hyperthyroidism seen here.
• C. A somatic activating TSH receptor mutation causes a toxic adenoma (solitary nodule), not a diffusely enlarged gland with extrathyroidal signs like proptosis.
• E. Anti-TPO antibodies are common in autoimmune thyroid disease but impair hormone synthesis rather than stimulate the gland, and do not explain the hyperthyroid picture.

The clinical picture of a diffusely enlarged, firm, nontender goiter with primary hypothyroidism (high TSH, low free T4) in a middle-aged woman is classic for Hashimoto thyroiditis. The diagnosis is confirmed by detecting circulating anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies, which reflect the autoimmune lymphocytic infiltration of the gland with formation of germinal centers seen on histology. Anti-TPO antibodies are present in over 90% of patients and are the most sensitive serologic marker used in clinical practice. Histology would show a dense lymphocytic infiltrate with germinal center formation and Hürthle cell change, but serologic antibody testing is the practical confirmatory test.

• A. Calcitonin is a marker for medullary thyroid carcinoma, unrelated to this presentation.
• B. Thyroglobulin is a tumor marker used to monitor for recurrence of differentiated thyroid cancer, not to diagnose autoimmune thyroiditis.
• C. Ultrasound can show a heterogeneous gland but does not confirm the autoimmune etiology as specifically as antibody testing.
• E. Radioactive iodine uptake is used to characterize nodules or hyperthyroidism, not to confirm autoimmune hypothyroidism.

Subacute (de Quervain) granulomatous thyroiditis typically follows a viral upper respiratory infection and presents with a painful, tender thyroid gland, fever, and an elevated ESR. Follicular cell damage releases preformed thyroid hormone, causing transient hyperthyroidism with a low TSH, but radioactive iodine uptake is characteristically decreased because the inflamed gland is not actively synthesizing new hormone. Histology shows granulomatous inflammation with multinucleated giant cells surrounding disrupted follicles. The condition is self-limited, typically followed by a transient hypothyroid phase and eventual recovery of euthyroid status.

• A. Acute suppurative thyroiditis is caused by bacterial infection, presents with high fever and systemic toxicity, and is rare, typically in immunocompromised or anatomically predisposed patients.
• B. Hashimoto thyroiditis presents with a painless, firm goiter and usually causes hypothyroidism rather than acute painful hyperthyroidism.
• D. Graves disease causes a nontender goiter with increased, not decreased, radioactive iodine uptake.
• E. Riedel thyroiditis causes a hard, woody, fibrotic thyroid that can mimic malignancy, without the painful tenderness or antecedent viral illness described here.

Methimazole is preferred for most of pregnancy, but it is avoided specifically during the first trimester because it is associated with a teratogenic embryopathy that includes aplasia cutis of the scalp and choanal or esophageal atresia. Propylthiouracil (PTU) is therefore used during the first trimester instead, despite carrying its own risk of rare but severe hepatotoxicity, because the fetal malformation risk with methimazole outweighs that concern during organogenesis. After the first trimester, patients are typically switched back to methimazole because of the lower risk of maternal hepatotoxicity. Both drugs inhibit thyroid peroxidase, blocking oxidation and organification of iodide to decrease new thyroid hormone synthesis.

• B. Hepatotoxicity is the adverse effect of PTU, the drug chosen for this patient, not the one being avoided.
• C. Fetal hypothyroidism can occur with either antithyroid drug if maternal dosing is excessive, and is not the specific teratogenic malformation being referenced.
• D. Agranulocytosis can occur with either thionamide and is not the specific first-trimester teratogenic concern that led to choosing PTU.
• E. Peripheral neuropathy is not a characteristic adverse effect of either thionamide drug.

Agranulocytosis is a rare, idiosyncratic adverse effect of both propylthiouracil and methimazole, thought to result from an immune-mediated reaction in which the drug or a reactive metabolite acts as a hapten, triggering antibody formation against neutrophils or their precursors and leading to peripheral destruction. It typically develops within the first few months of therapy and presents with fever and sore throat, as in this patient, requiring immediate discontinuation of the drug and supportive care. This is distinct from a dose-dependent toxic marrow effect, since agranulocytosis can occur even at low or standard doses. Patients should be counseled to seek care promptly for fever or sore throat while on thionamide therapy.

• A. Megaloblastic changes relate to vitamin B12 or folate deficiency, not thionamide-induced agranulocytosis.
• B. The reaction is idiosyncratic and immune-mediated rather than a direct, dose-dependent toxic effect on marrow stem cells.
• D. Thyroid hormone excess does not directly cause neutrophil apoptosis; this is an adverse drug effect rather than a consequence of the thyrotoxic state itself.
• E. Hypersplenism causing sequestration is not the mechanism of thionamide-associated agranulocytosis.

Papillary thyroid carcinoma is the most common thyroid malignancy and is characterized histologically by papillary architecture, nuclei with finely dispersed chromatin producing an "empty" or ground-glass appearance ("Orphan Annie eye" nuclei), nuclear grooves, and psammoma bodies, which are laminated, concentrically calcified structures corresponding to the microcalcifications seen on ultrasound. It arises from follicular epithelial cells and often spreads via lymphatic rather than hematogenous routes, frequently presenting with cervical lymphadenopathy. The characteristic nuclear features, rather than invasion patterns, are the key diagnostic criteria, distinguishing it from follicular carcinoma, which requires evidence of capsular or vascular invasion on histology.

• A. Anaplastic carcinoma shows highly pleomorphic, undifferentiated cells with a rapidly growing, aggressive mass, not the organized papillary architecture described.
• B. Multinodular goiter shows hyperplastic follicles of varying size without the malignant nuclear features or psammoma bodies described.
• C. Follicular carcinoma shows follicular architecture without papillary fronds or psammoma bodies, and diagnosis requires demonstrating capsular or vascular invasion.
• D. Medullary carcinoma arises from parafollicular C cells and shows amyloid stroma on histology, not psammoma bodies or Orphan Annie eye nuclei.